Michael R. Megna, an officer of Kiniksa Pharmaceuticals International, plc, filed a Form 144 Notice of Proposed Sale of Securities on October 30, 2026, disclosing plans to sell 47,540 Class A ordinary shares through Charles Schwab & Co., Inc.

Key Highlights

  • Seller and role: Michael R. Megna is identified as an officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA).
  • Shares proposed for sale: 47,540 Class A ordinary shares with an aggregate market value of $4,559,561.00, according to the filing.
  • Shares outstanding: The filing reports 48,836,965 Class A ordinary shares outstanding.
  • Acquisition sources: 16,365 shares were acquired on March 16, 2024 via restricted stock lapse; 31,175 shares were acquired on October 30, 2026 via employee stock option exercise, paid through a cashless exercise.
  • Prior sales: Megna sold 4,600 shares on September 3, 2026 for gross proceeds of $369,380.00 in the three months preceding this filing.
  • Rule 10b5-1 plan: The filing indicates a trading plan adoption date of July 30, 2026.
  • Approximate sale date: October 30, 2026, with the filing noting shares "may be sold over various dates."

Megna's Proposed Share Sale: Acquisition Sources and Plan Details

According to the Form 144 filing, Michael R. Megna, an officer of Kiniksa Pharmaceuticals International, plc, proposed to sell 47,540 Class A ordinary shares through broker Charles Schwab & Co., Inc., located at 3000 Schwab Way, Westlake, TX 76262. The filing lists an aggregate market value of $4,559,561.00 for the proposed sale. The issuer, Kiniksa Pharmaceuticals International, plc, is traded on NASDAQ and reported 48,836,965 Class A ordinary shares outstanding at the time of the notice.

The filing identifies two separate acquisition tranches underlying the proposed sale. A block of 16,365 shares was acquired on March 16, 2024 through a restricted stock lapse, with equity compensation listed as the nature of payment. A second block of 31,175 shares was acquired on October 30, 2026 through an employee stock option exercise, paid via broker payment for a cashless exercise. The filing's remarks note that "the shares reported on this filing were acquired and paid for between 03/16/2024 and 09/01/2026 and may be sold over various dates."

Regarding recent sales activity, the filing discloses that Megna sold 4,600 shares on September 3, 2026 for gross proceeds of $369,380.00 during the three months prior to this notice. The filing also indicates that the proposed sale is made in reliance on a Rule 10b5-1 trading plan or instruction adopted on July 30, 2026. By signing the Form 144, Megna represented, as of the plan adoption date, that he did not know of any material adverse information regarding the issuer's current and prospective operations that had not been publicly disclosed.

What Was Disclosed

Kiniksa Pharmaceuticals International, plc officer Michael R. Megna filed a Form 144 on October 30, 2026, proposing to sell 47,540 Class A ordinary shares valued at $4,559,561.00 in aggregate, sourced from a 2024 restricted stock lapse and a same-day option exercise, under a Rule 10b5-1 plan adopted July 30, 2026.